Quantum BioPharma Ltd. (NASDAQ: QNTM) is advancing its lead compound, Lucid-MS, toward a randomized, double-blind, placebo-controlled Phase 2 clinical trial in multiple sclerosis (MS) following clearance from the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) application. The FDA's decision marks a critical inflection point for the company and for the MS treatment landscape, where existing therapies largely rely on immunomodulation rather than direct repair of damaged myelin.
Lucid-MS is a patented, first-in-class, non-covalent inhibitor of peptidyl arginine deiminase 2 (PAD2). The enzyme PAD2 is implicated in the breakdown of myelin, the protective sheath around nerve fibers that is progressively destroyed in MS. By inhibiting PAD2, Lucid-MS aims to prevent and potentially reverse demyelination — the underlying cause of neurological disability in MS — without broadly suppressing the immune system. This mechanism differentiates it from current MS drugs, which typically modulate or suppress immune activity and carry risks of infection and other side effects. If successful in later-stage trials, Lucid-MS could represent a paradigm shift by addressing the disease's root pathology.
The IND clearance also underscores the potential of Quantum BioPharma's research collaboration with Massachusetts General Hospital and Harvard Medical School. That collaboration involves the [¹⁸F]3F4AP PET imaging tracer, which is being evaluated as a method to visualize and measure demyelination. Such a tool could provide clinicians with a non-invasive biomarker for disease progression and treatment response, enhancing both trial design and patient care.
The company's progress comes amid a broader wave of innovation in areas of high unmet medical need. Novartis AG (NYSE: NVS) recently received FDA approval for Pluvicto® in combination with an androgen receptor pathway inhibitor for certain patients with metastatic hormone-sensitive prostate cancer. Merck & Co. Inc. (NYSE: MRK) had its supplemental Biologics License Application for ENFLONSIA™ accepted by the FDA to expand its indication for certain children at increased risk for severe respiratory syncytial virus disease. TG Therapeutics Inc. (NASDAQ: TGTX) initiated a Phase 2 trial of BRIUMVI® in adults with treatment-resistant schizophrenia, while Bristol-Myers Squibb Company (NYSE: BMY) reported positive Phase 2 results from the registrational QUINTESSENTIAL trial evaluating arlocabtagene autoleucel in heavily pretreated relapsed and refractory multiple myeloma. These developments collectively highlight a dynamic period for biopharmaceutical companies targeting serious diseases.
Quantum BioPharma is dedicated to building a portfolio of innovative assets for challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company focuses on Lucid-MS. Preclinical models have shown the compound to prevent and reverse myelin degradation. Quantum also invented UNBUZZD™ and spun out its over-the-counter version to Unbuzzd Wellness Inc., retaining a 19.84% ownership stake as of March 31, 2026, and royalty rights of 7% of sales until payments total $250 million, after which the royalty drops to 3% in perpetuity. The company retains 100% of rights to develop similar products for pharmaceutical and medical uses.
For investors, the FDA's clearance of the IND for Lucid-MS is a significant de-risking event that opens the door to human trials in a major indication. The Phase 2 trial will test whether Lucid-MS's novel mechanism translates into clinical benefit for MS patients — a question with blockbuster potential if answered affirmatively. The outcome could also validate PAD2 inhibition as a therapeutic strategy for other demyelinating conditions. More information about Quantum BioPharma is available in the company's newsroom at https://ibn.fm/QNTM. The full press release can be viewed at https://ibn.fm/lCey9.
